GlassScriptPhysician profile
Cathy Lynn Koger
NPI 1902194871
$182,344.92
in general payments reported to CMS, 2019-2025
36 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $16K · 2021: $31K · 2022: $26K · 2023: $24K · 2024: $33K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $5,781 · Consulting Fee: $4,250 · Travel and Lodging: $3,230 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,080.00 |
| Food and Beverage | $5,781.34 |
| Consulting Fee | $4,250.00 |
| Travel and Lodging | $3,229.58 |
| Education | $115.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $161,660.61 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Ucb, INC. | $9,314.87 | 2021-2025 | Bimzelx, Cimzia |
| Celgene Corporation | $2,975.16 | 2019 | |
| Abbvie INC. | $1,624.12 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $782.09 | 2019-2025 | Ilumya, Winlevi |
| Amgen INC. | $705.00 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $556.43 | 2019-2025 | |
| Genzyme Corporation | $548.84 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $493.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $474.81 | 2021-2024 | Sotyktu |
| Janssen Biotech, INC. | $462.14 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $442.17 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $442.17 | 2019-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $268.15 | 2020-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $243.80 | 2019-2025 | Cabtreo, Jublia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $207.55 | 2019-2025 | Seysara, Klisyri |
| Vyne Pharmaceuticals INC. | $188.34 | 2020-2021 | |
| Biofrontera INC. | $163.44 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $107.69 | 2022-2025 | Opzelura |
| Organon LLC | $98.83 | 2025 | Vtama |
| Dermavant Sciences, INC. | $84.10 | 2023-2024 | Vtama |
| Dermira, INC. | $74.38 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $53.23 | 2024-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $50.19 | 2021-2023 | Valchlor |
| Botanix Sb INC | $44.38 | 2025 | Sofdra |
| Genentech USA, INC. | $39.40 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $38.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.31 | 2022-2023 | Spevigo |
| Mission Pharmacal Company | $30.46 | 2019 | |
| Journey Medical Corporation | $27.69 | 2025 | |
| Allergan, INC. | $24.31 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $23.43 | 2019 | |
| Qiagen, LLC | $19.04 | 2022 | |
| Verrica Pharmaceuticals INC. | $13.28 | 2023 | Ycanth |
| Mayne Pharma Commercial LLC | $12.83 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Koger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.